2024
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America.
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America. Journal Of Psoriasis And Psoriatic Arthritis 2024, 24755303241302070. PMID: 39583219, PMCID: PMC11583168, DOI: 10.1177/24755303241302070.Peer-Reviewed Original ResearchBody surface areaInternational Psoriasis CouncilSystemic therapySystemic psoriasis treatmentsDisease severity criteriaTopical therapyPsoriasis treatmentTherapy candidatesCorEvitas Psoriasis RegistrySystemic therapy initiationTreatment-naive patientsSeverity criteriaReal-world studyCross-sectional studyDisease severity indicatorsPatient-reported outcome measuresPlaque psoriasisPsoriasis RegistryTherapy initiationSystemic treatmentRegistry visitPASI scoreClinical characteristicsClinical decision-makingPsoriasis severitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola J, Strober B, Gottlieb A, Mostaghimi A, Hawkes J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s488. DOI: 10.25251/skin.8.supp.488.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementSystemic medicationsConventional systemic treatmentsAverage body surface areaTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageSystemic therapyDosing regimenSystemic treatmentPediatric patientsPustular psoriasisExtent of involvementSpesolimabWeek 4Skin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober B, Merola J, Gottlieb A, Elewski B, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s489. DOI: 10.25251/skin.8.supp.489.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementWeek 4Disease historyAverage body surface areaTreating generalized pustular psoriasisYear prior to enrollmentLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabDisease courseSkin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober B, Merola J, Gottlieb A, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s491. DOI: 10.25251/skin.8.supp.491.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementTreating generalized pustular psoriasisLife-threatening skin diseaseArea of involvementSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabSkin symptomsContinuous treatmentPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsTreatmentInvolvementBody regionsSix-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world study
2023
41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials
Strober B, Kircik L, Green L, Lockshin B, Brown P, Tallman A. 41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials. Journal Of The American Academy Of Dermatology 2023, 89: ab92. DOI: 10.1016/j.jaad.2023.07.371.Peer-Reviewed Original ResearchPS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial
Warren R, Strober B, Lebwohl M, Foley P, Langley R, Davis L, Hoepken B, Szilagyi B, Ciaravino V, Bewley A. PS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial. British Journal Of Dermatology 2023, 188: ljad113.366. DOI: 10.1093/bjd/ljad113.366.Peer-Reviewed Original ResearchOpen-label extensionBody surface areaSevere plaque psoriasisWeek 16Plaque psoriasisOpen-label extension trialTreatment-related adverse eventsDermatology Life Quality IndexPASI 90 responseMaintenance of efficacyHealth-related qualityYear 3Long-term efficacyLife Quality IndexLack of efficacyYear 1HRQoL benefitsNonresponder imputationOLE entryPsoriasis AreaResponder rateAdverse eventsWeek 24Study treatmentAnalysed patientsBimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley R, Warren R, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. British Journal Of Dermatology 2023, 188: 749-759. PMID: 36967713, DOI: 10.1093/bjd/ljad035.Peer-Reviewed Original ResearchConceptsOngoing open-label extensionSevere plaque psoriasisBody surface areaDermatology Life Quality IndexWeek 16Plaque psoriasisNonresponder imputationPASI 100Investigator's Global Assessment 0/1Open-label extension trialDLQI 0/1 responsePASI 90 respondersOpen-label extensionHealth-related qualityLong-term efficacyLife Quality IndexLong-term treatmentLoss of responseYear 3Absolute PASIPASI 90Efficacy outcomesClinical responsePsoriasis AreaExtension trial
2022
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis G, Warren R, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal Of Dermatology 2022, 188: 330-340. PMID: 36751950, DOI: 10.1093/bjd/ljac089.Peer-Reviewed Original ResearchConceptsExposure-adjusted incidence ratesTreatment-emergent adverse eventsAdverse eventsDurable improvementMajority of TEAEsDiscontinuation of biologicsNew safety findingsPASI 90 respondersSevere plaque psoriasisHealth-related qualityBody surface areaTime of switchAbsolute PASIIIIb trialPASI 100PASI 90Skin clearancePlaque psoriasisWeek 48Clinical responseEfficacy outcomesPsoriasis AreaSafety findingsWeek 24Week 52Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. Dermatology And Therapy 2022, 12: 1351-1365. PMID: 35551619, PMCID: PMC9100304, DOI: 10.1007/s13555-022-00740-y.Peer-Reviewed Original ResearchBiologic-naive patientsInvestigator's Global AssessmentBody surface areaClinical outcomesUS real-world settingGlobal assessmentBiologic-experienced patientsEffectiveness of secukinumabMethodsThis observational studyPrior biologic useFirst-line therapyProportion of patientsSeverity Index scoreTreatment of psoriasisSimilar improvementsBiologic experiencePsoriasis RegistryResultsBetween 2015Secukinumab treatmentIGA scoreBiologic useClinical characteristicsPatient characteristicsPsoriasis AreaPatient cohortSex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Goldburg S, Chen R, Langholff W, Lafferty K, Gooderham M, de Jong E, Strober B. Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 132-139. PMID: 39296535, PMCID: PMC11361528, DOI: 10.1177/24755303221099848.Peer-Reviewed Original ResearchPsoriasis Longitudinal AssessmentDisease characteristicsDermatology Life Quality Index scoresDisease severitySystemic therapy-naïve patientsLife Quality Index scoresLongitudinal assessmentPhysician global assessmentSystemic steroid therapyLifestyle risk factorsTherapy-naïve patientsNonmelanoma skin cancerObjective disease severityBody surface areaHistory of anxietyQuality Index scoresQuality of lifeChi-square testPsoriasis characteristicsSteroid therapySevere psoriasisTherapy-naïveDisease durationBiologic-naïvePatient characteristics
2021
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. New England Journal Of Medicine 2021, 385: 2219-2229. PMID: 34879448, DOI: 10.1056/nejmoa2103629.Peer-Reviewed Original ResearchConceptsPrimary end pointPatient-reported outcomesTapinarof creamGlobal assessment scoreBody surface areaPlaque psoriasisWeek 12End pointPGA responseAdverse eventsPGA scoreMean changeSkin barrier protein filaggrinSecondary efficacy end pointsUpper respiratory tract infectionPhysician Global Assessment scoreNumeric rating scale scoreTotal body surface areaTotal scoreEfficacy end pointIdentical phase 3Local adverse eventsSymptom diary scoresProportion of patientsSecondary end pointsThe Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Papp K, Lebwohl M, Kircik L, Pariser D, Strober B, Krueger G, Berk D, Navale L, Higham R. The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. Dermatology And Therapy 2021, 11: 1079-1083. PMID: 34236691, PMCID: PMC8322185, DOI: 10.1007/s13555-021-00572-2.Peer-Reviewed Original Research
2020
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis
Gold L, Hansen J, Patel D, Veverka K, Strober B. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. Journal Of The American Academy Of Dermatology 2020, 83: 131-138. PMID: 32430142, DOI: 10.1016/j.jaad.2020.02.077.Peer-Reviewed Original ResearchConceptsCal/BD foamSevere psoriasisWeek 4Disease severityPhysician global assessmentProportion of patientsBody surface areaSpearman correlationTherapeutic response measuresCalcipotriol/Dipropionate foamMild psoriasisPlaque psoriasisPsoriasis AreaBland-Altman plotsPsoriasis severityTherapeutic responseMean improvementWeek 1PsoriasisGlobal assessmentSeverity IndexInterrater reliabilitySeverityPASICharacterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
Van Voorhees A, Mason M, Harrold L, Guo N, Guana A, Tian H, Herrera V, Strober B. Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2020, 32: 907-915. PMID: 32027197, DOI: 10.1080/09546634.2020.1720586.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistrySevere psoriasisPsoriasis RegistryInsufficient respondersPsoriasis body surface areaBody surface areaLogistic regression modelingReal-world studyBiologic therapyPatient demographicsUS patientsBiologic treatmentDisease characteristicsInadequate responseInsufficient responsePatientsPsoriasisDecreased likelihoodRespondersRegistryVisitsRegression modelingEnrollmentFollowOutcomes
2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball A, Barker J, Blauvelt A, Members and Councilors I, Bourcier M, Carvalho A, Cohen A, Foley P, Evans C, Gisondi P, Griffiths C, El-Sayed M, Eschevarria C, Finlay A, Kalb R, Leonardi C, Lynde C, Murphy R, Murakami M, Okubo Y, Prens E, Puig L, Seyger M, Skov L, Terui T, Valenzuela F, Ward N, Wu J, Zheng M. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2019, 82: 117-122. PMID: 31425723, DOI: 10.1016/j.jaad.2019.08.026.Peer-Reviewed Original ResearchConceptsPsoriasis severityInternational Psoriasis CouncilSystemic therapyTopical therapyConsensus statementUndertreatment of psoriasisBody surface areaPast treatment historyPsoriasis involvementPsoriasis patientsClinical studiesTreatment decisionsDelphi consensusEligibility criteriaTreatment historyPatientsSevere categoryTherapySeverity categoriesSeverity definitionsSeverityDichotomous definitionSeverity classificationDelphi approachUndertreatmentFeasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council
Strober B, van de Kerkhof P, Callis Duffin K, Poulin Y, Warren R, de la Cruz C, van der Walt J, Stolshek B, Martin M, de Carvalho A. Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. American Journal Of Clinical Dermatology 2019, 20: 699-709. PMID: 31228013, PMCID: PMC6764927, DOI: 10.1007/s40257-019-00458-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overClinical Decision-MakingCommunicationCross-Sectional StudiesFeasibility StudiesFemaleHumansInternational CooperationMaleMiddle AgedPatient Reported Outcome MeasuresPhysician-Patient RelationsPsoriasisQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeYoung AdultConceptsPsoriasis Symptom InventoryStatic Physician's Global AssessmentBody surface areaPsoriasis-affected body surface areaSymptom InventoryPatient-reported outcome measuresPatient treatment prioritiesPhysician global assessmentPatient-physician communicationClinical care settingsInternational Psoriasis CouncilPSI total scorePatient-physician relationshipMild psoriasisPsoriasis signsSevere psoriasisUntreated patientsModerate psoriasisDermatology clinicPsoriasis severityPatient visitsSame visitTreatment decisionsCare settingsOutcome measuresUS real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Strober B, Germino R, Guana A, Greenberg J, Litman H, Guo N, Lebwohl M. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2019, 31: 333-341. PMID: 31035822, DOI: 10.1080/09546634.2019.1603361.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesCorrona Psoriasis RegistryGlobal assessment scoreBody surface areaReal-world effectivenessPsoriasis RegistryReal-world studySecukinumab treatmentDisease severityInvestigator's Global Assessment scoreMajority of patientsTreatment of psoriasisQuality of lifeEligible patientsSecukinumabPatientsSignificant improvementFollowAssessment scoresRegistryVisitsWork productivityPsoriasisDaily activitiesTreatmentImpact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry
Strober B, Greenberg J, Karki C, Mason M, Guo N, Hur P, Zhao Y, Herrera V, Lin F, Lebwohl M. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open 2019, 9: e027535. PMID: 31005939, PMCID: PMC6500315, DOI: 10.1136/bmjopen-2018-027535.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiological ProductsBody Surface AreaCross-Sectional StudiesEfficiencyFemaleHumansLinear ModelsMaleMiddle AgedMultivariate AnalysisPainPain MeasurementPatient Reported Outcome MeasuresPsoriasisQuality of LifeRegistriesSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeUnited StatesConceptsPatient-reported outcomesBody surface areaCorrona Psoriasis RegistrySevere psoriasisPsoriasis severityPsoriasis RegistryReal-world settingPatient-reported clinical symptomsWorse patient-reported outcomesGlobal assessmentMore severe psoriasisSystemic psoriasis treatmentsInvestigator's Global AssessmentHealth-related qualityMultivariable regression analysisMultivariable regression modelsCross-sectional analysisWPAI domainsWPAI scoresIGA scoreProspective registryAdult patientsIgA levelsDLQI scoreUS patients
2017
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. British Journal Of Dermatology 2017, 177: 1562-1574. PMID: 28755394, DOI: 10.1111/bjd.15857.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBody surface areaABP 501Week 16Adverse eventsAntidrug antibodiesPlaque psoriasisBiosimilar ABP 501New safety signalsPercentage of patientsPhase III trialsSimilar clinical efficacySeverity Index scorePercentage body surface areaLong-term resultsEuropean Medicines AgencyPASI 50PASI improvementWeek 52III trialsPsoriasis AreaAdalimumab patientsImmunogenicity profileClinical efficacyPatient population